Delving into the Latest Updates on Dendritic Cells(Radboud University Medical Center) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Dendritic cell vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsCongenital DisordersDigestive System Disorders+ [3]

Active Indication

Ovarian Epithelial CarcinomaHereditary Nonpolyposis Colorectal Cancer

Inactive Indication

MelanomaMetastatic endometrial cancerUveal Melanoma

Originator Organization

Radboud University Medical Center

Active Organization

Radboud University Medical Center

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Prevention of infectious diseases through immunization is one of the greatest achievements of modern medicine. Nonetheless, considerable challenges remain for improving the efficacy of existing vaccines for therapeutic immunizations for diseases such as cancer. The investigators were amongst the first groups worldwide that introduced tumor antigen-loaded dendritic cell (DC)-based vaccines in the clinic1-3. Effective immune responses and favorable clinical outcomes have indeed been observed4-7. Thus far, mainly conventional in vitro generated monocyte-derived DCs (moDC) have been used in clinical trials worldwide. In the past 14 years the investigators have treated more than 375 patients and proven that DC therapy is feasible and non-toxic. The investigators observed that long lasting tumor specific T cell-mediated immunological responses are clearly linked to increased progression free survival as well as overall survival8.
In conclusion, based on all these observations the investigators are convinced that pDC and myDC employ different, and probably more optimal mechanisms to combat cancer. In addition, based on in vitro data and preclinical studies that suggest that blood pDC and myDC act synergistically, the investigators hypothesize that the combination of myDC and pDC may induce stronger anti-tumor immune responses as compared to pDC or myDC alone, or moDC.

Start Date08 Apr 2019

Sponsor / Collaborator

Radboud University Medical Center

[+1]

JPRN-jRCTc040190103

/ CompletedPhase 2IIT

Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase II clinical trial - Immunotherapy against malignant brain tumor

Start Date02 Sep 2013

Sponsor / Collaborator-

100 Clinical Results associated with Dendritic Cells(Radboud University Medical Center)

Login to view more data

100 Translational Medicine associated with Dendritic Cells(Radboud University Medical Center)

Login to view more data

100 Patents (Medical) associated with Dendritic Cells(Radboud University Medical Center)

Login to view more data

21

Literatures (Medical) associated with Dendritic Cells(Radboud University Medical Center)

01 Mar 2025·Biomedicine & Pharmacotherapy

Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy

Review

Author: Kalhor, Naser ; Fayazi Hosseini, Nashmin ; Heidari, Reza ; Chamanara, Mohsen ; Al-Musawi, Sharafaldin ; Sheykhhasan, Mohsen ; Ahmadieh-Yazdi, Amirhossein ; Poondla, Naresh ; Yang, Piao ; Mahaki, Hanie ; Manoochehri, Hamed ; Malih, Sara ; Akbari, Mohammad ; Tanzadehpanah, Hamid ; Dirbaziyan, Ashkan

In the modern time, cancer immunotherapies have increasingly become vital treatment options, joining long-established methods like surgery, chemotherapy, and radiotherapy treatment. Central to this emerging approach are dendritic cells (DCs), which boast a remarkable ability for antigen presentation. This ability is being leveraged to modulate T and B cell immunity, offering a groundbreaking strategy for tackling cancer. However, the percentage of patients experiencing meaningful benefits from this treatment remains relatively low, underscoring the ongoing necessity for further research and development in this field. This review offers a comprehensive analysis of the present-day progress in dendritic cell (DC)-based vaccines and recent efforts to enhance their efficacy. We explore the intricacies of DC function, from antigen capture to T cell stimulation, and discuss the outcomes of both preclinical and clinical trials across various cancer types. While the results are promising, the real-world application of DC-based vaccines is still nascent, posing multiple challenges that need to be overcome. These obstacles include optimizing the methods for DC generation and antigen loading, overcoming the immunosuppressive nature of the tumor microenvironment, and enhancing specificities of the immunologic response through personalized vaccines. The review concludes by emphasizing prospective opportunities for future research and emphasizing the critical need for extensive clinical trials. These trials are essential to validate the effectivity of DC-based vaccines and solidify their role in the broader spectrum of cancer immunotherapy options.

31 Dec 2024·Human Vaccines & Immunotherapeutics

Bibliometric analysis of dendritic cell-based vaccines over the past 15 years

Article

Author: Wu, Yinghua ; Liu, Bo ; Long, Zhi ; Lu, Jiping ; Zhong, Liangchen

Dendritic cells, which are crucial for inducing T-cell responses, are pivotal in current immunotherapy strategies aiming to replenish depleted T cells within the tumor microenvironment to combat tumors. Consequently, dendritic cell vaccine-based cancer therapies have garnered significant attention. Through bibliometric analysis, we examined research trends in this field. We searched the Web of Science core database and identified 16,476 articles on dendritic cell-based vaccines published from January 1, 2009, to December 30, 2023. The United States leads in this research domain, with Emory University being a prominent collaborator. The Journal of Immunology is the primary publication outlet, and Banchereau, J emerges as the most influential author. Recent hot keywords include nanoparticle, delivery, cancer vaccine, and clinical trial, indicating that cancer immunotherapy research, especially dendritic cell-based vaccines, is poised to become a future trend and hotspot.

01 Dec 2021·Computational Biology and ChemistryQ4 · BIOLOGY

Modeling codelivery of CD73 inhibitor and dendritic cell-based vaccines in cancer immunotherapy

Q4 · BIOLOGY

Article

Author: Pourgholaminejad, Arash ; Arabameri, Abazar

Dendritic cells (DCs) are the dominant class of antigen-presenting cells in humans; therefore, a range of DC-based approaches have been established to promote an immune response against cancer cells. The efficacy of DC-based immunotherapeutic approaches is markedly affected by the immunosuppressive factors related to the tumor microenvironment, such as adenosine. In this paper, based on immunological theories and experimental data, a hybrid model is designed that offers some insights into the effects of DC-based immunotherapy combined with adenosine inhibition. The model combines an individual-based model for describing tumor-immune system interactions with a set of ordinary differential equations for adenosine modeling. Computational simulations of the proposed model clarify the conditions for the onset of a successful immune response against cancer cells. Global and local sensitivity analysis of the model highlights the importance of adenosine blockage for strengthening effector cells. The model is used to determine the most effective suppressive mechanism caused by adenosine, proper vaccination time, and the appropriate time interval between injections.

100 Deals associated with Dendritic Cells(Radboud University Medical Center)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Epithelial Carcinoma	Phase 2	Netherlands	Radboud University Medical Center	17 Mar 2023
Hereditary Nonpolyposis Colorectal Cancer	Phase 2	Netherlands	Radboud University Medical Center	01 Oct 2010
Uveal Melanoma	Phase 1	Netherlands	Radboud University Medical Center	01 Jun 2009
Metastatic endometrial cancer	Preclinical	Netherlands	Radboud University Medical Center	08 Apr 2019
Melanoma	Preclinical	-	Radboud University Medical Center	01 Mar 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SITC2019	Not Applicable	Pancreatic Cancer WT1 \| MUC1	23	DC vaccination+OK-432+GEM	chfgquhfwz(ttamgjkivy) = The treatment was well tolerated and none of the patients experienced more than grade 3 adverse events during the treatment period dedsrlghak (xhbbpkbvwv )	Positive	01 Nov 2019
				DC vaccination+OK-432+S-1